0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV208.64%PremiumMay 17, 2024Expiry Date5.07Intrinsic Value100Multiplier-5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Gain Therapeutics Stock Discussion
NEWS
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Positive results from the SAD part of the Phase 1 Clinical Trial of GT-02287.
GT-02287 was well tolerated with no serious adverse events.
Achieved appropriate plasma exposure levels after oral administration.
GT-02287 has the potential to slow or stop Parkinso...
7 MINUTES AGO, 2:00 PM EST
VIA GLOBENEWSWIRE
Gain Therapeutics Announces Preclinical Data Demonstrating GT-02287 Restored Motor Function In Mouse Models Of Parkinson's Disease
• $Customers Bancorp(CUBI.US)$ : KBW Upgrades to Outperform from Market Perform - PT $80 (from $72)
• $Fortinet(FTNT.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $395 (from $364)
• $Hoegh LNG(HMLP.US)$ : Stifel Upgrades to Buy from Hold - PT $9.50 (from $8)
• $Randolph Bancorp(RNDB.US)$ : Compass Point Upgrades to Buy from Neutral - PT $27 (from $23)
• $SiteOne Landscape Supply(SITE.US)$ : UBS Upgrades to Neutral from Sell - PT $165 (fr...
No comment yet